<DOC>
	<DOCNO>NCT02206607</DOCNO>
	<brief_summary>Study B1621015 characterize bioavailability , tolerability pharmacodynamics three modify release formulation PF-04937319 compare immediate release material-sparing-tablet ( IR MST ) formulation adult type 2 diabetes .</brief_summary>
	<brief_title>Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet ( IR MST ) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adults type 2 diabetes , stable background metformin therapy either alone combination another oral antidiabetic agent ( OAD ) exclude thiazolidinediones ( TZDs ) Patients cardiovascular event within 6 month screen Patients diabetic complication Female subject pregnant plan become pregnant Subjects unstable medical condition ( eg , hypertension )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>bioavailability</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>PF-04937319</keyword>
</DOC>